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Bone marrow-derived stromal/stem cells (BMSCs) have recently been characterized as mediators of tissue regeneration after injury. In
addition to preventing fibrosis at the wound site, BMSCs elicit an angiogenic response within the fibrin matrix. The mechanistic
interactions between BMSCs and invading endothelial cells (ECs) during this process are not fully understood. Using a three-dimensional,
fibrin-based angiogenesis model, we sought to investigate the proteolytic mechanisms by which BMSCs promote vessel morphogenesis.
We find that BMSC-mediated vessel formation depends on the proteolytic ability of membrane type 1-matrix metalloproteinase
(MT1-MMP). Knockdown of the protease results in a small network of vessels with enlarged lumens. Contrastingly, vessel morphogenesis
is unaffected by the knockdown of MMP-2 and MMP-9. Furthermore, we find that BMSC-mediated vessel morphogenesis in vivo follows
mechanisms similar to what we observe in vitro. Subcutaneous, cellular fibrin implants in C.B-17/SCID mice form aberrant vasculature
when MMPs are inhibited with a broad-spectrum chemical inhibitor, and a very minimal amount of vessels when MT1-MMP proteolytic
activity is interrupted in ECs. Other studies have debated the necessity of MT1-MMP in the context of vessel invasion in fibrin, but this
study clearly demonstrates its requirement in BMSC-mediated angiogenesis.
J. Cell. Physiol. 227: 3546–3555, 2012.  2012 Wiley Periodicals, Inc.
The success of engineering viable, functional tissues is
contingent on the ability to vascularize the implantable tissue.
Limited diffusion of oxygen and other nutrients within tissues
greater than 1 cm diminishes the efficacy of simple, specialized
tissue implants, thereby necessitating the need to establish
penetrating vascular networks within these tissues (Carmeliet
and Jain, 2000; Zandonella, 2003). In vivo hypoxic conditions
typically result in cells of a mesenchymal lineage mobilizing
endothelial cells (ECs) to degrade and invade ischemic tissue
through specific proteolytic pathways (Fuchs et al., 2001;
Rehman et al., 2004). Understanding the mechanisms that
govern this intricate process will be beneficial for the field of
regenerative medicine and treating pathologies characterized
by aberrant vascularization.
Angiogenesis is vascularization that evolves from new blood
vessels sprouting from a parent vessel. Proteases are intimately
involved in every phase of angiogenesis starting with the initial
degradation of the parent vessel’s basement membrane to the
final pruning of excess vasculature (Ghajar et al., 2008b). The
extracellular matrix (ECM) provides several mechanical and
biochemical cues that influence the angiogenic process,
including the presentation of protease-cleavable sites that allow
interstitial cells and ECs to remodel the ECM. Protease
expression, localization, and activation are tightly regulated
throughout angiogenesis in a manner that results in focused
ECM degradation at the invading vessel front (Kroon et al.,
1999; Yana et al., 2007). Matrices that are unable to be
remodeled by ECs prevent vessel formation and require the
integration of protease-sensitive peptides to accommodate
vascularization (Moon et al., 2010; Phelps et al., 2010). The
sequence of these peptides should be catered to the protease
expression profile of the cells within the implant model. Our
group has previously demonstrated that different interstitial
cells elicit ECs to use different proteases during angiogenesis
(Ghajar et al., 2010; Kachgal and Putnam, 2011); therefore, the
choice of interstitial cells is an important factor to consider in
designing vascular constructs.
Bonemarrow-derived stromal/stem cells (BMSCs) are a type
of mesenchymal stem cell that have been extensively
characterized in terms of their multipotency (Hauner et al.,
1987; Grigoriadis et al., 1988; Ferrari et al., 1998). In addition to
their ability to differentiate into a range of tissues, we, along
with others, have shown that BMSCs are also capable of
promoting angiogenesis (Ghajar et al., 2006; Au et al., 2008;
Ghajar et al., 2008a; Ghajar et al., 2010), thereby making them
an ideal cell type in engineering specialized, vascularized tissue.
BMSCs promote angiogenesis via matrix metalloproteinase
(MMP) degradation of the ECM.When coculturedwith BMSCs,
endothelial MMP-2, MMP-9, andmembrane-type 1 (MT1)-MMP
upregulation is concomitant with vessel invasion. Additionally,
pharmacological inhibition of MMPs completely eliminates
BMSC-mediated vessel formation (Ghajar et al., 2010).
The present study explores the specific protease
dependency in BMSC-mediated angiogenesis in fibrin. Using
RNA interference and an established angiogenesis coculture
model (Nakatsu and Hughes, 2008), we show that MT1-MMP is
required for BMSC-mediated angiogenesis, whereas the soluble
proteases, MMP-2 and MMP-9, are not. Furthermore, MT1-
MMP localizes to endothelial tip cells of invading vessels.
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Knockdown of EC MT1-MMP results in the formation of a
minimal amount of large, abnormal vessels. Similar abnormal
vasculature is found when MMPs are inhibited within BMSC/EC
in vivo implants.We also find that EC proliferation is affected by
MT1-MMP independent of its catalytic activity. By isolating its
proliferation capacity from its proteolytic ability, we find that
the catalytic activity of MT1-MMP is, in fact, required for
endothelial vessel invasion. These data specifically demonstrate
that EC MT1-MMP is absolutely required for BMSC-mediated
angiogenesis in fibrin.
Materials and Methods
HUVEC isolation and cell culture
Human umbilical vein endothelial cells (HUVECs) were isolated
from freshly harvested umbilical cords as previously described
(Ghajar et al., 2006). Briefly, the vein was flushed with sterile
phosphate buffered saline (PBS) and then incubated with 0.1%
collagenase type I (Worthington Biochemical, Lakewood, NJ) for
20min at 378C. The digestion product and subsequent PBS wash
were collected and centrifuged. The cell pellet was resuspended in
EGM-2 (Lonza, Walkersville, MD), plated onto T-25 flasks, and
allowed to attach overnight. PBS was used to wash away any red
blood cells the following day. HumanBMSCs (Lonza)were cultured
in low glucose (1 g/L) DMEM supplemented with 10% fetal bovine
serum (FBS, Invitrogen, Carlsbad, CA) and 1% antibiotic-
antimycotic (Mediatech, Manassas, VA). Normal human lung
fibroblasts (NHLFs, Lonza) were cultured in Medium 199
(Invitrogen) supplemented with 10% FBS and 1% antibiotic–
antimycotic. All cultures were incubated at 378C and 5% CO2.
Media were changed every 2–3 days and cells were harvested with
0.05% trypsin–EDTA (Invitrogen). HUVECs were used prior to
passage six, while BMSCs and NHLFs were used prior to passage
ten.
Fluorescent labeling of cells
To facilitate visualization and quantification of vessel networks,
HUVECs were stably transduced with a gene encoding the
mCherry fluorescent protein using the Phoenix Ampho Retrovirus
Expression System (Orbigen, SanDiego,CA). PhoenixAmpho cells
were transfected with a pBMN-mCherry plasmid using
Lipofectamine 2000 (Invitrogen). Retroviral supernatant was
collected, passed through a 0.45mm syringe filter, and
supplemented with 5mg/ml Polybrene (Millipore, Billerica, MA)
before being incubated with HUVECs for a period of 8 h. This
process was repeated the following day. NHLFs were transduced
with a GFP adenovirus by adding an adenoviral stock to the culture
media for a period of 2 days.
RNA interference
MMP-2 and MMP-9 gene expression levels were attenuated by
transducing HUVECs with the HuSH-29 shRNA (OriGene
Technologies, Rockville, MD) specific for those two genes. Short-
hairpin RNA plasmids for MMP-2 (50-TATTACCTGAAGCTG-
GAGAACCAAAGTCT-30), MMP-9 (50-GCCTGCAACGTGAA-
CATCTTCGACGCCAT-30), and a non-targeting control
(50-GCACTACCAGAGCTAACTCAGATAGTACT-30) were
separately packaged into the Phoenix Ampho Retrovirus System
(Orbigen) in a similar fashion as the aforementioned mCherry
plasmid. HUVECs were incubated with the filtered retroviral
supernatant for a period of 10 h each day for four consecutive days.
A lentiviral shRNA plasmid against MT1-MMP (50-GCGATGAA-
GTCTTCACTTACTTCT-30) and a corresponding scrambled
shRNA (50-CAACAAGATGAAGAGCACCAA-30) plasmid were
graciously provided by Dr. Mina J. Bissell. These plasmids were
packaged into lentiviral particles using the Virapower Lentiviral
Expression System (Invitrogen). The lentiviral shRNA plasmids,
along with the packaging plasmids, were transfected into 293FT
cells using Lipofectamine 2000. After a 48-h incubation period, the
lentiviral supernatant was collected and passed through a 0.45-mm
syringe filter. The supernatant was concentrated by
ultracentrifugation at 77,000g for 90min, followed by resuspension
in PBS. HUVECs were incubated in EGM-2 supplemented with
5mg/ml Polybrene for 30min at 378C prior to the addition of the
concentrated lentiviral supernatant. The lentiviral medium was
removed after 48 h and replaced with fresh EGM-2. Selection of
shRNA-expressing HUVECs was achieved by culturing HUVECs in
the presence of 1mg/ml puromycin (Sigma-Aldrich, St. Louis, MO)
for a period of 4–6 days. MT1-MMP knockdown in BMSCs was
carried out via electroporation. Small-interfering RNAs against
MT1-MMP (50-AACAGGCAAAGCTGAT GCAGA-30) and a
scrambled control (50-AAGTGATCAAGCACCGAAGAG-30)
were graciously provided by Dr. Stephen J. Weiss. Each respective
siRNA was introduced into BMSCs at a concentration of 40 nM
using the Nucleofector Kit for Human Mesenchymal Stem Cells
and Nucleofector Device (Lonza).
MT1-MMP constructs
Plasmids encoding for MT1-MMP constructs with a deleted
catalytic domain (DCAT-MT1) and the full-length form (Full-MT1)
were previously characterized (Mori et al., 2009) and graciously
donated by Dr. Mina J. Bissell and Dr. Stephen J. Weiss,
respectively. In addition, a fluorescently-tagged MT1-MMP
construct was created by EGFP fusion onto the C-terminus of the
full length form. These constructs were subsequently cloned into
the pBMN retroviral vector. Retroviral particles were created
using the aforementioned Phoenix Ampho Expression system and
HUVECs were transduced with the retroviral supernatant for a
period of 10 h for two consecutive days.
Reverse transcription and quantitative
polymerase chain reaction
Total RNAwas isolated from cells using the SVTotal RNA Isolation
System (Promega, Madison, WI) and quantified using a Nanodrop
ND-1000 (Thermo Fisher Scientific, Rochester, NY). Equal
amounts of total RNA from each sample in its respective
experimental group were used to create first-strand cDNA using
the ImProm-II Reverse Transcription System (Promega).
Quantitative PCR (qPCR) was performed using a 7500 Fast Real-
Time PCR System and TaqManUniversal PCRMasterMix (Applied
Biosystems, Carlsbad, CA). Predesigned qPCR primers for human
MMP-2, MMP-9, MT1-MMP, and 18s rRNAwere selected from the
TaqMan Gene Expression Assays database (Applied Biosystems).
The DDCTmethod was used to assess the relative quantity of each
target gene.
Fibrin tissue assembly
Cytodex 3microcarrier beads (Sigma-Aldrich) were subjected to a
series of washes in EGM-2, and then added to aHUVEC suspension
in a 5-ml polypropylene tube at a ratio of 400 cells/bead. To
promote cell coating onto the beads, the suspension was mixed by
gentle pipetting every 30min for 3.5 h. Afterwards, the bead
solution was collected and transferred into an upright T-25 flask
with an additional 1.5ml EGM-2. This flask was cultured overnight
at 378C and 5% CO2 to allow any remaining suspended cells to
attach to the culture surface. The following day, fibrinogen
(Sigma-Aldrich) was dissolved in serum-free EGM-2 to a final
concentration of 2.5mg/ml. The solution was passed through a
0.22mm syringe filter before being combined with the appropriate
interstitial cell type (100,000 cells/ml) and HUVEC-coated beads
(50 beads/ml). For each gel to be constructed, 10ml of a 50U/ml
thrombin solution (Sigma-Aldrich) was added to the center of a
well of a 24-well tissue culture plate. Immediately prior to
polymerization, 5% FBS was added to the fibrinogen solution
followed by addition of 500ml to each of the thrombin-spotted
wells. The solution was initially allowed to set for 5min at room
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temperature followed by incubation at 378C and 5% CO2 for an
additional 30min. Following polymerization, fully-supplemented
EGM-2 and any chemical inhibitors were added. Medium
( chemical inhibitors) was changed at day 1, 3, and 5 post-
assembly. For the purposes of high-magnification imaging, tissue
constructs were also formed in 8-well chambered coverglass with
number 1 thickness.
Fluorescence imaging and quantification
Fluorescent images were captured using an Olympus IX81
equipped with a Disc Scanning Unit and a 100W high-pressure
mercury burner (Olympus America, Center Valley, PA), a
Hamamatsu Orca II CCD camera (Hamamatsu Photonics, K.K.,
Hamamatsu City, Japan), and Metamorph Premier software
(Molecular Devices, Sunnyvale, CA). Total vessel network
formation was assessed 7 days post-assembly. Imaged beads were
chosen at randomprovided that theymet the condition that vessels
emanating from a given bead did not form anastomoseswith vessels
from adjacent beads. At least five beads per condition were imaged
at low magnification (4) for each independent experiment. Total
vessel network length was measured utilizing the Angiogenesis
Tube Formation module in Metamorph. Minimum and maximum
widths were entered into the program to differentiate vessels from
noise and the bead, respectively. Cell proliferation was assessed by
capturing four non-overlapping, lowmagnification (4) images per
condition of HUVECs stained with 200 ng/ml 40,6-diamidino-2-
phenylindol (DAPI, Sigma-Aldrich). The total number of cells were
counted using the Count Nuclei module in Metamorph and then
normalized to the first time point assessed.
In vivo vascularization and histology
Animal procedures were performed in accordance with the
National Institutes of Health’s guidelines for laboratory animal
usage following a protocol approved by the University of Michigan
University Committee on Use and Care of Animals. Tissue
constructs were prepared for injection by combining 1.5 million
HUVECs and 1.5 million BMSCs in 300ml of a 10mg/ml fibrinogen/
EGM-2 (minus FBS) solution. C.B-17/SCID male mice (Taconic,
Hudson, NY) aged 4 weeks were used for all experiments. A
prepared anesthetic/analgesic cocktail of ketamine (100mg/kg),
xylazine (10mg/kg), and buprenorphine (0.05mg/kg) (Western
Medical Supply, Arcadia, CA) was delivered via an intraperitoneal
injection. The dorsal area of each animal was subsequently shaved
and sterilized with betadine (Thermo Fisher Scientific).
Immediately prior to implant injection, 15mL FBS, 6ml of a 50U/ml
thrombin solution, and any chemical inhibitors were added to the
precursor solution. The gel precursor solutions were injected
subcutaneously into the rear, lateral flanks so that each mouse
carried two implants. The mice were kept stationary for 5min to
aid in the initial polymerization of the gel solution and then
transferred to their recovery cages. Mice were sacrificed at 7 days
post-implantation and implants were retrieved and immediately
placed in 10% formalin (Sigma-Aldrich). The implants were
transferred into PBS the following day and stored at 48C. Samples
were forwarded to AML Laboratories (Baltimore, MD) for
histological sectioning and hematoxylin and eosin (H&E) staining.
Quantification of perfused vessels was assessed independently by
two individuals who were blinded to the study and sample
conditions. Each individual was asked to count the number of
vessels filled with erythrocytes within several 40 H&E-stained
images.
Other reagents used
The broad spectrum MMP inhibitor GM6001 (EMD Chemicals,
Gibbstown,NJ) was used at a greater than 100-fold excess (10mM)
of its IC50 concentrations against MMP-2, MMP-9, and MT1-MMP
(Uttamchandani et al., 2007). To minimize evaluating the off-target
effects that individual pharmacological inhibitors may cause, the
more potent MMP inhibitor BB2516 (Tocris Bioscience, Ellisville,
MO) was used at 3.3mM, which represents a comparable level of
inhibition to 10mM GM6001, based on the supplier’s IC50 values
for the sameMMPs. Additionally, 100mMofGM6001was added to
the fibrinogen gel precursor solutions to inhibit MMP activity in
vivo. Equal volumes of dimethyl sulfoxide (DMSO, Sigma-Aldrich)
were used as the vehicle control for these experiments.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software (GraphPad Software, La Jolla, CA). Data are presented as
mean standard deviation. One-way analysis of variance with a
Bonferroni post test was used to assess statistical significance
between data sets. Statistical significance was assumed when
P 0.05.
Results
BMSC-mediated angiogenesis in fibrin is
not dependent on soluble MMPs
To systematically assess the requirement of specific proteases
in BMSC-mediated angiogenesis, we first used retroviral
shRNAs against the soluble MMPs, MMP-2 and MMP-9, to
attenuate their expression in HUVECs, and then cocultured
these cells with BMSCs in our angiogenesis model. Knockdown
ofMMP-2 expression, asmeasured through qPCR,was found to
be 76% relative to the non-targeting shRNA (shNT, Fig. 1A).
Expression of MMP-9 was not detected in either shNT or
shMMP-9 HUVECs. This is consistent with our previous RT-
PCR findings that MMP-9 expression in HUVECs was seen only
when cocultured with BMSCs and not when cultured alone (as
they were when RNA lysates were obtained for qPCR) (Ghajar
et al., 2010). Regardless, neither shMMP-2 nor shMMP-9
HUVECs displayed any difference in vessel sprouting with
respect to shNT HUVECs (Fig. 1B,C). A pan-specific MMP
inhibitor, BB2516, was used as a control that drastically inhibits
vessel sprouting in BMSC/HUVEC cocultures.
MT1-MMP expression in HUVECs is required
for BMSC-mediated angiogenesis in fibrin
Previous studies from our group and others have shown a
positive correlation between vessel sprouting and MT1-MMP
expression (Hotary et al., 2002; Ghajar et al., 2006, 2010; Yana
et al., 2007). Knockdown of HUVEC MT1-MMP expression via
lentiviral shRNA was assessed to be 72% relative to the
scrambled shRNA (shSCR, Fig. 2A). HUVECs transduced with
the shMT1 lentivirus demonstrated a 72% reduction in total
vessel network sprouting relative to the shSCR HUVECs when
both were cocultured with BMSCs (Fig. 2B,C). The minimal
vessels that did sprout in the shMT1 HUVEC condition
displayed a qualitatively thickened morphology
(Fig. 2C arrowheads). This abnormal vessel morphology is
phenotypically similar towhatwehave observedwhen using the
pan-specific MMP inhibitor GM6001 in adipose-derived stem
cell/HUVEC (Kachgal and Putnam, 2011) and fibroblast/
HUVEC cocultures (Fig. 3A). In these cultures, total vessel
network length is not affected by MMP-inhibition, but the
formed vessels are thicker than their respective controls.
Fibroblast/HUVEC cocultures also showed altered, and
seemingly insufficient, pericytic coverage of vessels whenMMPs
were inhibited (Fig. 3B).
MT1-MMP has previously been shown to localize to the tip of
invading vessels in collagen gels, thereby imparting a polarity
between endothelial tip cells and vessel stalk cells (Yana et al.,
2007).We created anMT1-MMP-GFP fusion construct so as to
visualize the localization of MT1-MMP in sprouting vessels.
HUVECs were transduced with the retroviral MT1-MMP-GFP
construct and cocultured with BMSCs within our angiogenesis
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model. At day 3, MT1-MMP localized to the tips of nascent
vessels (Fig. 4 top panel arrow). High-magnification imaging of
the endothelial vessel tips reveals further MT1-MMP
expression within the filopodia extending from the vessel tip
(Fig. 4 bottom panel arrowheads).
To determine whether MT1-MMP expression in the
interstitial cell compartment is also required for angiogenesis,
we introduced an siRNA against MT1-MMP into BMSCs via
electroporation. Knockdown, as assayed by qPCR, was shown
to be 89% relative to BMSCs electroporated with a scrambled
siRNA (siSCR, Fig. 5A). Coculture of siMT1 BMSCs with wild
type (WT)-MT1-MMP HUVECs showed no significant
difference in vessel sprouting relative to siSCR BMSCs
(Fig. 5B,C).
Catalytic activity of MT1-MMP in HUVECs is required
for BMSC-mediated angiogenesis in fibrin
Recent studies have postulated non-proteolytic functions for
MT1-MMP (Mori et al., 2009; Lu et al., 2010). Therefore,
knockdown of MT1-MMP may have an effect on HUVECs
outside of its proteolytic capability. Since EC proliferation is
also a hallmark of the angiogenic process, especially at theMT1-
MMP-rich vessel tip (Yana et al., 2007), we assessed the
Fig. 1. BMSC-mediated angiogenesis is notmediated byMMP-2 and
MMP-9. HUVECs, transduced with mCherry and either an shRNA
againstMMP-2,MMP-9, or a non-targeting (NT) control, were coated
on microcarrier beads and cultured within 2.5mg/ml fibrin gels
interspersed with BMSCs. A: Expression level of MMP-2 in HUVECs
after knockdown was assessed via qPCR. MMP-9 expression was not
detected in either shNT or shMMP-9 HUVECs. B: Representative
day 7 images of vessel formation in the presence of either a DMSO
vehicle control (left column) or 3.3mM of MMP-inhibitor, BB2516
(right column). C:Quantification of total vessel network length at day
7. MMM refers to P £ 0.001 in comparison to the respective controls.
Scale barU 100mm. [Color figure can be seen in the online version of
this article, available at http://wileyonlinelibrary.com/journal/jcp]
Fig. 2. Knockdown of MT1-MMP in HUVECs diminishes vessel
sprouting and effects vessel diameter. A: Expression level of MT1-
MMP in HUVECS after knockdown as assessed via qPCR. B:
Quantification of total vessel network length at day 7. C: day 7 images
of mCherry-expressing HUVECs, transduced with either an shRNA
against MT1-MMP or a scrambled control (shSCR), on microcarrier
beads cocultured with BMSCs within a fibrin matrix either in the
presence of a DMSO vehicle control (left panel) or 3.3mM BB2516
(right panel). Arrowheads indicate thickened vessels as a result of
MT1-MMP knockdown. MM in (A) refers to P £ 0.01 with respect to the
scrambled control. MMM in (C) refers to P £0.001 with respect to the
shSCRvehicle control condition. ## and### refer toP £0.01 and0.001
in comparison to the vehicle control conditions, respectively. Scale
barU 100mm. [Color figure can be seen in the online version of this
article, available at http://wileyonlinelibrary.com/journal/jcp]
JOURNAL OF CELLULAR PHYSIOLOGY
B M S C - M E D I A T E D A N G I O G E N E S I S R E Q U I R E S M T 1 - M M P 3549
proliferative capacity of shMT1-transduced HUVECs. HUVECs
were transduced with two separate lentiviral shRNA clones
against MT1-MMP and proliferation was assayed at day 3 by
counting DAPI-stained nuclei and normalizing them to their
respective day 1 count. The shMT1 clones 348 and 1644 had
knockdown efficiencies of 41 and 89%, respectively (Fig. 6A),
and significantly decreasedHUVECproliferation by 35 and 44%,
respectively (Fig. 6B,C).
In order to delineate the effects of MT1-MMP on BMSC-
mediated angiogenesis, we sought to determine whether the
lack of sprouting identified in BMSC/shMT1HUVEC cocultures
(Fig. 2B,C) was due to MT1-MMP’s proteolytic ability or its
effect on EC proliferation. HUVECs were transduced with a
retrovirus encoding for either an MT1-MMPmutant lacking the
catalytic domain (DCAT-MT1) or a control encoding for the
full-length construct (Full-MT1, Fig. 6C). Total MT1-MMP
expression in Full-MT1 and DCAT-MT1 HUVECs was five and
85-fold greater than WT cells, respectively (Fig. 6D). When
cocultured with BMSCs, WT, and Full-MT1 HUVECs displayed
no significant difference in total vessel network formation;
whereas DCAT-MT1 HUVECs exhibited a dramatic decrease
relative to the former two conditions (Fig. 6E,F). Interestingly,
DCAT-MT1 vessels did not exhibit the thickened morphology
characteristic of those formed from shMT1 HUVECs. The
proliferative effects of MT1-MMP on HUVECs were effectively
segregated from its proteolytic ability, as both Full-MT1 and
DCAT-MT1 HUVECs displayed similar proliferation potentials
(Fig. 6G).
MMP activity is required to establish normalized
vasculature in vivo
To assess the MMP-dependency of vascularization in vivo, we
subcutaneously injected a fibrin gel precursor solution
containing BMSCs andHUVECs alongwith the broad-spectrum
MMP inhibitor GM6001 or a DMSO vehicle control into C.B-
17/SCID mice. H&E staining of retrieved implants at day 7
revealed abnormal vasculature in implants thatwere dosedwith
GM6001. The vessels appeared large relative to the vehicle
control and tended to coalesce into pockets throughout the
implant, characteristic of a hemangioma (Fig. 7A). Implants from
both conditions formed anastomoses with the host vasculature
as evidenced by the presence of erythrocytes within vessel
lumens (Fig. 7A arrows); however, several of the vessels in the
Fig. 3. MMP-inhibition in fibroblast-mediated angiogenesis results in thickening of vessels and altered pericytic coverage of vessels. A: day 7
imagesoffluorescently-transducedHUVECsonmicrocarrierbeadscoculturedwithlungfibroblastswithinafibrinmatrixeitherinthepresenceofa
DMSO vehicle control (left panel) or 10mM of MMP-inhibitor, GM6001 (right panel). Arrowheads indicate thickened vessels as a result of MMP
inhibition. B: Fibroblasts (green) were cultured with HUVECs (red) in the presence of DMSO (top row) or GM6001 (bottom row) for 7 days.
Pericytic associationoffibroblastswith thevesselswasassesedviahigh-magnification confocalmicroscopy. Scalebar in (A)U 100mm.Scalebar in
(B)U 20mm. [Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/journal/jcp]
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GM6001 condition exhibited incomplete walls resulting in
extravasation of erythrocytes into the interstitial matrix
(Fig. 7A arrowheads).
In order to more specifically assess the effects of MT1-MMP
in vivo, DCAT-MT1 HUVECs and BMSCs were implanted
subcutaneously within a fibrin gel. Gross visualization of
implants retrieved at day 7 revealed amarked decrease in blood
perfusion within the DCAT-MT1 HUVEC/BMSC implants as
compared to the Full-MT1 HUVEC/BMSC implants (Fig. 7B).
Subsequent H&E staining of implant sections validated these
findings as Full MT1 HUVEC/BMSC implants displayed an
abundant number of perfused vessels whereas DCAT-MT1
HUVEC/BMSC implants had significantly less vessel formation
(Fig. 7C,D).
Discussion
This study explored the proteolytic mechanisms that guide
BMSC-mediated angiogenesis within a fibrin matrix. We have
previously found that chemical inhibition of MMPs in BMSC/
HUVEC cocultures abrogated vessel formation (Ghajar et al.,
2010). Here, we used RNA interference to demonstrate that
EC invasion and subsequent normal vessel formation are
dependent on the proteolytic activity of MT1-MMP, and do not
absolutely require MMP-2 or MMP-9. Knockdown of
endothelial MT1-MMP severely limited vessel network
formation, but did allow formation of a short network of vessels
with abnormally enlarged lumens; this phenotype is similar to
that observed whenMMPs were inhibited in fibroblast/HUVEC
angiogenesis models. Furthermore, these findings were also
validated in vivo, as pharmacological inhibition of MMPs
resulted in the formation of abnormal vasculature in cellular
fibrin implants, and specific deletion of the proteolytic domain
of MT1-MMP significantly hindered any vessel formation.
Heterotypic interactions between BMSCs and ECs have
been previously shown to influence vessel formation and
invasion within fibrin matrices (Ghajar et al., 2010). We, along
with other groups, have previously shown that the expression
of MMP-2, MMP-9, and MT1-MMP are all upregulated in BMSC/
EC cocultures (Hanemaaijer et al., 1993; Brooks et al., 1996;
Ghajar et al., 2006; Ghajar et al., 2010), but only the knockdown
of the membrane-bound MT1-MMP inhibited vessel invasion.
This is consistentwith our previous study that found that TIMP-
2, but not TIMP-1, abrogated vessel sprouting in BMSC/HUVEC
cocultures (Ghajar et al., 2010). These data suggest that vessel
invasion requires anchored proteases at the vessel tip,
degrading the ECM in a tightly guided fashion, rather than
soluble proteases whose activities are likely not as spatially
Fig. 4. Endothelial vessel tips strongly express MT1-MMP. HUVECs were transduced with mCherry and an MT1-MMP-GFP construct, coated
on microcarrier beads, then cocultured with BMSCs within a fibrin matrix. Day 3 images show strong expression of MT1-MMP in the tip of a
budding vessel (toppanel, arrow).High-magnification imaging shows furtherMT1-MMP localization tovessel tips aswell as to extendingfilopodia
(bottompanel, arrowheads).Toppanel scalebarU 100mm.Bottompanel scalebarU 20mm.[Colorfigurecanbe seen in theonline versionof this
article, available at http://wileyonlinelibrary.com/journal/jcp]
Fig. 5. BMSC-derived MT1-MMP is not required for vessel
sprouting. BMSCs were electroporated with siRNA against either
MT1-MMP or a scrambled control (siSCR) and then cocultured with
mCherry-expressingHUVECs onmicrocarrier beads. A: BMSCMT1-
MMPexpression levels as assessed via qPCR.B:Quantificationof total
vessel network length at day 7. C: Representative day 7 images of
vessel formation. MM refers to P £0.01 with respect to the scrambled
control. Scale barU 100mm. [Color figure can be seen in the online
version of this article, available at http://wileyonlinelibrary.com/
journal/jcp]
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restricted. This theory is consistent with our previous reports
that fibroblast and adipose-derived stem cell-mediated
angiogenesis can proceed through a urokinase plasminogen
activator (uPA)-directed mechanism (Ghajar et al., 2010;
Kachgal and Putnam, 2011). Plasminogen activation into the
serine protease plasmin occurs through two mechanisms: uPA
or tissue plasminogen activator (tPA). The former pathway
requires initial binding of uPA to the cell membrane-anchored
uPA receptor, thereby sequestering plasmin activation and
proteolysis to the immediate vicinity of the cell surface.
Conversely, activation by tPA does not require prior binding to
a cell surface receptor, and results in a global activation of
plasmin. We have observed bulk degradation of fibrin gels
without vessel formation in cultures that express excessive tPA
(unpublished observations). MMP-2 and MMP-9 have
demonstrated the ability to localize to the cell surface through
the binding of aVb3 and CD44, respectively; however, the
endothelial expression of thesemolecules within a fibrinmatrix
is unclear as they are classically known as adhesion molecules
for fibronectin and hyaluronic acid, respectively (Brooks et al.,
Fig. 6. MT1-MMP knockdown also reduces HUVEC proliferation, but its proteolytic activity is required for angiogenesis. HUVECs were
transducedwithseparateshRNAclonesagainstMT1-MMPorascrambledcontrol.A:MT1-MMPexpressionasassessedviaqPCR.B:DAPI-stained
HUVEC cultures were counted at day 3 and normalized to the count at day 1 to assess proliferation. C: HUVECswere transducedwith either an
MT1-MMPconstructwithadeletedcatalyticdomain (DCAT-MT1)or the full-lengthconstruct (Full-MT1).D:TotalMT1-MMPexpression relative
towild type (WT)HUVECsasassessedviaqPCR.TheseHUVECsalongwithaWTcontrolwere transducedwithmCherrybeforebeingcoatedon
microcarrier beads and cocultured with BMSCs within a fibrin matrix. Representative images (E) and quantification (F) of total vessel network
length at day 7. G: Full-MT1 and DCAT-MT1 HUVECs were DAPI-stained and counted at day 3 and normalized to the day 1 count to assess
proliferation.MMM in (A)referstoP £ 0.001foreachgroup incomparisontoeachothergroup.MandMM in (B)refertoP £ 0.05and0.01 incomparisonto
the shSCR condition, respectively. MM and MMM in (D) refer to P £0.01 and 0.001 in comparison to theWT control, respectively. MMM in (F) refers to
P £0.001with respect toeachof theother twogroups.ScalebarU 100mm.[Colorfigurecanbeseen in theonline versionof this article, availableat
http://wileyonlinelibrary.com/journal/jcp]
JOURNAL OF CELLULAR PHYSIOLOGY
3552 K A C H G A L E T A L .
1996; Yu and Stamenkovic, 1999). The upregulation of MMP-2
and MMP-9 that we have previously documented could be a
consequence of both MMPs being activated by MT1-MMP (Sato
et al., 1994; Toth et al., 2003), and play a role in assisting MT1-
MMP with ECM degradation, but our data here show that they
are nonessential to the overall angiogenic process in a fibrin
matrix.
In addition to its effect on outward vessel invasion, MT1-
MMP knockdown yielded vessels that exhibited a thicker
morphology than their control counterparts. Similarly enlarged
Fig. 7. MMPs are required for establishing normal in vivo vasculature. BMSCs andHUVECswere subcutaneously injectedwithin a fibrinmatrix
into C.B-17/SCID mice. A: Erythrocytes (arrows), indicative of anastomosis with host vasculature, can be observed in hematoxylin and eosin-
stainedsectionsof implantsretrievedatday7.Erythrocyteextravasationfromvesselswithdiscontinuouslumenalwallscanbeobservedinimplants
pre-dosed with GM6001 (arrowheads). B: day 7 retrieval of DCAT-MT1 HUVEC/BMSC implants revealed a reduced level of vascularization
compared to Full-MT1 HUVEC/BMSC implants. C: H&E-stained sections reveal extensive, perfused vasculature in Full-MT1 HUVEC/BMSC
implants and no vascularization of DCAT-MT1 HUVEC/BMSC implants. Insets show magnified images of respective sections. Arrow shows
erythrocytes within vessel lumen. D: Quantification of perfused vessels permillimeter. Scale bars in (A and C)U 100mm. Scale in (B) is shown in
inches. Scale bar in (C, inset)U 20mm. [Color figure can be seen in the online version of this article, available at http://wileyonlinelibrary.com/
journal/jcp]
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vessels were observed whenMMP activity was disrupted with a
broad spectrum MMP inhibitor in fibroblast/EC cocultures,
correlating with a decrease in fibroblast pericytic coverage of
the vessels. This finding of enlarged vessels also translated to
the in vivo setting where we showed hemangioma-like
vasculature development when MMPs were inhibited. While
the contribution of macrophage-derived proteases to tumor
angiogenesis has been shown (Hildenbrand et al., 1995;
Gocheva et al., 2010a,b), these are unlikely to be a major
determinant of vascularization in this scenario; deletion of the
catalytic domain of HUVEC MT1-MMP was sufficient to
completely inhibit vessel formation. These data suggest that
MT1-MMP also exerts an effect on regulating vessel diameter,
and perhaps stabilizing neovessels. Perivascular association of
mural cells is known to stabilize nascent vasculature and
influence vessel distention (Hellstrom et al., 2001; Morikawa
et al., 2002). Prior studies have shown that MT1-MMP
expression in the mural cell compartment is required for
migration and association of mural cells with neovessels
(Filippov et al., 2005; Lehti et al., 2005; Sounni et al., 2010);
however, knockdown of MT1-MMP in BMSCs did not
noticeably affect vessel diameter, suggesting rather that MT1-
MMP within the EC compartment is responsible for regulating
vessel diameter, at least within fibrin matrices. Another theory
for this phenomenon involves the local concentration of
vascular endothelial growth factor (VEGF) in the vessel
microenvironment. High local concentrations of VEGF have
been shown to promote hemangioma formation (Ozawa et al.,
2004).With increasing evidence suggesting that MMPs serve an
additional role in releasing matrix-bound growth factors
(Egeblad andWerb, 2002; Heissig et al., 2003), it is possible that
MMP inhibition in ECs prevents the release and internalization
of VEGF; this might lead to sustained high local concentrations
of VEGF that support a pro-angiogenic phenotype rather than
switching to a maturation phenotype.
MT1-MMP had an additional effect on the proliferation of
ECs. Knockdown of HUVEC MT1-MMP resulted in an
unexpected reduction of their proliferative capacity. ECs at
vessel tips had previously been shown to express a higher level
of MT1-MMP and be more proliferative than vessel stalk cells
(Yana et al., 2007), but these have not been directly linked. Our
data showed a strong localization of MT1-MMP to the vessel
tips. These data, taken together, opened the possibility that the
lack of angiogenesis in MT1-MMP-deficient HUVECs was a
consequence of their decreased proliferation rather than
limited ECM degradation. To isolate MT1-MMP’s effect on
proliferation from its effect on ECM degradation, we
transduced HUVECs with a truncated form of MT1-MMP
lacking its catalytic domain. These cells had similar proliferation
potential as HUVECs transduced with full-length MT1-MMP,
yet displayed severely inhibited vessel network formationwhen
cocultured with BMSCs. Furthermore, DCAT-MT1 HUVECs
inhibited vessel formation within fibrin implants in vivo when
cocultured with BMSCs. These data clearly demonstrate that
MT1-MMP proteolytic activity is required for BMSC-mediated
vessel formation in fibrin matrices. Interestingly, DCAT-MT1
vessels did not exhibit enlarged lumens as shMT1 vessels did.
Beyond addressing key, underlying mechanisms involved in
BMSC-mediated angiogenesis, this work has implications
toward the design of biomaterials that support
neovascularization. As mentioned earlier, the ability to create
vascularized, specialized tissues might alleviate several of the
problems associated with ischemia-induced implant necrosis.
Our use of a fibrin matrix is predicated on its role as a
provisional matrix and site of angiogenesis in natural wound
healing (van Hinsbergh et al., 2001). Fibrin is also a natural
attractant of mesenchymal cells such as BMSCs (Clark, 2001;
Farrell and al-Mondhiry, 1997), which are thought to remain
quiescent until activated by tissue injury (Caplan, 2008; Crisan
et al., 2008), whereby they promote tissue regeneration instead
of fibrosis. Additionally, BMSCs are thought to differentiate
toward the lineage of the injured tissue to further support tissue
regeneration. However, the clinical use of fibrin as a biomaterial
has some potential limitations. Chief among these is the
sourcing of the precursor fibrinogen. Traditional fibrin-based
surgical adhesives source their fibrinogen, and associated
clotting factors, frompooled human plasma fractions, which can
incur the risk of viral transmission (Siedentop et al., 1985).
Obtaining fibrinogen from autologous sources greatly reduces
this risk, but is not always practical due to time constraints.
Another concern is bulk proteolysis of the fibrin by host
proteases following implantation. Current strategies require
the co-delivery of fibrinolytic inhibitors to prevent premature
ECM degradation (Webster and West, 2002), but for the
purposes of our vascular constructs, these inhibitors may
prevent matrix remodeling and vascularization altogether.
Recent efforts have been made to promote vessel formation
within synthetic matrices, which would potentially negate the
issues associated with natural material sourcing (Moon et al.,
2010; Phelps et al., 2010). In many cases, the degradability of
synthetic materials can be tuned via the inclusion of protease-
cleavable peptide sequences that allow for implanted or host
cells to remodel and migrate through an otherwise
impenetrable matrix (Lutolf et al., 2003; Raeber et al., 2005).
Most of these approaches incorporated a peptide that is
preferentially sensitive to MMP-2 (Turk et al., 2001; Seliktar
et al., 2004; Hanjaya-Putra et al., 2011); however, our findings
here suggest that synthetic polymer gels containing peptide
cross-links that are more specifically sensitive to MT1-MMP
may be better suited to support BMSC-mediated vessel
morphogenesis.
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